Site içinde arama yapın

EthanWalker bir ses eklendi Other
2026-10-23 22:16:07 - Translate -

Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...

0 Yorumlar 0 hisse senetleri 11 Views 0 önizleme

Please log in to like, share and comment!
RobertMitchell bir ses eklendi Health
2026-10-23 19:35:08 - Translate -

Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease tests
Roth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...

0 Yorumlar 0 hisse senetleri 7 Views 0 önizleme

Please log in to like, share and comment!
JasonWilliams bir ses eklendi Other
2026-10-23 15:43:10 - Translate -

Rithm Capital (RITM) distributable earnings slip to $0.55 a share as Newrez lending volume falls 19%
Rithm Capital Corp. (RITM) posted much higher GAAP profit on a swing in mortgage servicing values, but its non-GAAP earnings measure fell as funded mortgage volume dropped from the second quarter. Newrez funded $12.9 billion of mortgages in the third quarter, 19% less than in the second quarter and 21% less than a year earlier. Rithm Capital Corp. (RITM) disclosed the figure in its results for...

0 Yorumlar 0 hisse senetleri 8 Views 0 önizleme

Please log in to like, share and comment!